Document Detail


Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients with Refractory Crohn's Disease.
MedLine Citation:
PMID:  22885333     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND & AIMS: New therapeutic strategies are needed for patients with refractory Crohn's Disease (CD). We evaluated data from the Crohn's and T-regulatory Cell Study (CATS)1 to determine safety and efficacy of antigen-specific T regulatory (Treg) cells for treatment of refractory CD. METHODS: We performed a 12-week, open-labelled, multicenter, single injection, escalating dose, phase I and IIa clinical study in 20 patients with refractory CD. Ovalbumin-specific Treg cells (ova-Tregs) were isolated from patients' peripheral blood mononuclear cells (PBMC), exposed to ovalbumin, and administrated intravenously. Safety and efficacy were assessed using clinical and laboratory parameters. We evaluated proliferation of PBMC in response to ovalbumin. RESULT: sInjections of Ova-Tregs were well tolerated, with 54 adverse events (2 related to the test reagent) and 11 serious adverse events (3 related to the test reagent, all recovered). Overall, a response, based on a CD Activity Index (CDAI) reduction of 100 points, was observed in 40% of patients at Weeks 5 and 8. Six out of the 8 patients (75%) that received doses of 106 cells had a response, at Weeks 5 and 8, with statistically significant reduction in CDAI. In this group, remission (based on CDAI ≤ 150) was observed in 3/8 patients (38%) at Week 5 and 2/8 patients (25%) at Week 8. CONCLUSIONS: Administration of antigen-specific Treg cells to patients with refractory CD (CATS1) was well tolerated and had dose-related efficacy. The ovalbumin-specific immune response correlated with clinical response, supporting immune-suppressive mechanisms of ova-Tregs. The consistency of results among different assessment methods supports the efficacy of ova-Tregs; this immune therapy approach warrants further clinical and mechanistic studies in refractory CD. Eudract N° 2006-004712-44.
Authors:
Pierre Desreumaux; Arnaud Foussat; Matthieu Allez; Laurent Beaugerie; Xavier Hébuterne; Yoram Bouhnik; Maria Nachury; Valérie Brun; Hervé Bastian; Nathalie Belmonte; Michel Ticchioni; Agnès Duchange; Patricia Morel-Mandrino; Virginie Neveu; Nathalie Clerget-Chossat; Miguel Forte; Jean-Frédéric Colombel
Related Documents :
1997153 - Lymphatic fistula after vascular reconstruction: a case-control study.
15466793 - Peripheral high-flow arteriovenous vascular malformations: a single-center experience.
9232093 - A survey of the diagnostic and therapeutic management of patients with suspected pulmon...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-8
Journal Detail:
Title:  Gastroenterology     Volume:  -     ISSN:  1528-0012     ISO Abbreviation:  Gastroenterology     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374630     Medline TA:  Gastroenterology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Hepatogastroenterology and Centre d'Investigation Clinique, Huriez Hospital, Lille, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of bariatric surgery on glucose homeostasis and type 2 diabetes.
Next Document:  Hedgehog controls hepatic stellate cell fate by regulating metabolism.